Literature DB >> 12763516

Breast cancer and post-menopausal hormone therapy.

P Kenemans1, A Bosman.   

Abstract

From the introduction of post-menopausal hormone replacement therapy (HRT) there has been great concern that HRT could possibly increase the risk of breast cancer. Prolonged exposure to endogenous oestrogens undeniably increases the risk of breast cancer. Questions that are important and until now only partly answered, are the following. Are oestrogens tumour promoters, as they induce mitosis, lead to proliferation and, therefore, accelerated growth of clinically occult pre-existing tumours? In addition to this, are they genotoxic mutagenic carcinogens, or could they initiate tumours by way of accumulation of incessant DNA-replication damage mechanism? Opinions vary as to the effect of the addition of a progestogen. There is a multitude of different progestogens which could bind with differing affinity to progesterone receptor PR-A or PR-B, and which have different physiological functions via differential gene regulation. The action of a progestogen on the oestrogen-induced cellular mitotic activity could be synergistic or antagonistic (by different pathways: oestrogen receptor downregulation, activating of metabolic pathways within the breast or stimulation of apoptosis)? Over 60 observational studies and two randomized trials provide evidence that the small but significant increase in risk appears with long-term current post-menopausal hormone use. The addition of a progestogen does not decrease the risk as seen with oestrogens alone and might increase the risk further. It is not clear whether there is a difference in risk with sequentially combined versus continuously combined HRT. Many questions nevertheless still remain. Is the risk increase limited to lean women only? What about risk-modifying factors such as alcohol use and a positive family history for breast cancer? Are tumours detected under HRT less aggressive, is there a better prognosis and is the mortality not increased while morbidity is? And is HRT contraindicated for women with a positive family history for breast cancer or in those women who have been treated for breast cancer? And finally, are there alternative options for these women?

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763516     DOI: 10.1016/s1521-690x(02)00084-2

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  8 in total

Review 1.  Current breast cancer risks of hormone replacement therapy in postmenopausal women.

Authors:  Nirav R Shah; Tanping Wong
Journal:  Expert Opin Pharmacother       Date:  2006-12       Impact factor: 3.889

2.  TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.

Authors:  Florence Gizard; Romain Robillard; Barbara Gross; Olivier Barbier; Françoise Révillion; Jean-Philippe Peyrat; Gérard Torpier; Dean W Hum; Bart Staels
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

Review 3.  New progestogens: a review of their effects in perimenopausal and postmenopausal women.

Authors:  Régine Sitruk-Ware
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques.

Authors:  Karen Pazol; Mark E Wilson; Kim Wallen
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

5.  Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.

Authors:  Thiyagarajan Boopalan; Arunkumar Arumugam; Jacqueline Parada; Edward Saltzstein; Rajkumar Lakshmanaswamy
Journal:  Cancer Sci       Date:  2015-01       Impact factor: 6.716

Review 6.  Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.

Authors:  Carolyn L Smith; Richard J Santen; Barry Komm; Sebastian Mirkin
Journal:  Breast Cancer Res       Date:  2014-06-18       Impact factor: 6.466

7.  Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?

Authors:  Giovanni Grandi; Maria Chiara Del Savio; Valentina Boggio Sola; Francesca Monari; Chiara Melotti; Fabio Facchinetti
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

8.  Estrone-3-Sulfate Stimulates the Proliferation of T47D Breast Cancer Cells Stably Transfected With the Sodium-Dependent Organic Anion Transporter SOAT (SLC10A6).

Authors:  Emre Karakus; Daniel Zahner; Gary Grosser; Regina Leidolf; Cemal Gundogdu; Alberto Sánchez-Guijo; Stefan A Wudy; Joachim Geyer
Journal:  Front Pharmacol       Date:  2018-08-21       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.